Renal Disease Associated with Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is rarely associated with renal disease, but when it occurs, the most important manifestation is AA-type (secondary) amyloidosis, which can lead to nephrotic syndrome and end-stage renal failure. Other rare renal complications include glomerulonephritis and tubulointerstitial nephritis.
Primary Renal Manifestation: AA Amyloidosis
The most clinically significant renal complication of PMR is secondary (AA-type) amyloidosis, which develops from chronic inflammation 1, 2. This can progress rapidly—one case report documented development of nephrotic range proteinuria and deteriorating renal function within just 18 months of PMR symptom onset 1. The amyloid deposits are confirmed by immunohistochemical analysis showing AA-type protein 2.
Clinical Presentation of AA Amyloidosis in PMR:
- Nephrotic syndrome (heavy proteinuria)
- Progressive renal failure
- Can advance to end-stage renal disease requiring dialysis 3
- May occur despite aggressive treatment with steroids and other immunosuppressants 3
Other Rare Renal Manifestations
Glomerulonephritis
Diffuse endocapillary proliferative glomerulonephritis has been documented in PMR patients presenting with proteinuria and hematuria 4. This responds well to low-dose prednisolone (10 mg/day), with improvement in both urinary abnormalities and systemic symptoms 4.
Tubulointerstitial Nephritis
One case report documented acute tubulointerstitial nephritis in a PMR patient with concurrent subclinical Sjögren's syndrome 5. Gallium scintigraphy showed marked renal accumulation, and renal biopsy revealed lymphocytic infiltration. This responded to high-dose methylprednisolone 5.
Clinical Implications and Monitoring
The key clinical message is that renal involvement in PMR is extremely rare but carries serious prognostic implications when present 1. The most recent PMR guidelines 6 do not specifically address renal complications, as they focus on musculoskeletal manifestations and glucocorticoid management. However, the rarity of renal involvement should not lead to complacency.
Practical Monitoring Approach:
- Check baseline renal function (creatinine, eGFR) and urinalysis at PMR diagnosis
- Monitor for proteinuria during follow-up, particularly in patients with prolonged disease or inadequate inflammatory control
- Consider renal biopsy if significant proteinuria (>0.3 g/day) or hematuria develops 4
- Maintain vigilance in patients requiring prolonged glucocorticoid therapy, as persistent inflammation increases AA amyloidosis risk 1
Important Caveat:
The differential diagnosis must include vasculitis (particularly giant cell arteritis with renal involvement), as 5-10% of PMR patients develop GCA 6. Vasculitis can also cause renal disease and requires different management intensity.
Treatment Considerations
When renal disease is identified in PMR:
- AA amyloidosis: Requires aggressive control of underlying inflammation to halt amyloid deposition; prognosis is often poor once established 3, 2
- Glomerulonephritis: May respond to standard PMR glucocorticoid doses 4
- Tubulointerstitial nephritis: May require higher-dose glucocorticoids initially 5
The presence of renal complications should prompt consideration of glucocorticoid-sparing agents (methotrexate or IL-6 receptor inhibitors) to achieve better inflammatory control while minimizing long-term glucocorticoid toxicity 6, 7.